

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Impact of the COVID-19 pandemic on mortality trends in Japan: a reversal in 2021?

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-071785
Article Type:	Original research
Date Submitted by the Author:	16-Jan-2023
Complete List of Authors:	Tanaka, Hirokazu; National Cancer Center Japan, Division of Surveillance and Policy Evaluation Togawa, Kayo; National Cancer Center Japan Katanoda, Kota; National Cancer Center Japan
Keywords:	COVID-19, Epidemiology < TROPICAL MEDICINE, Public health < INFECTIOUS DISEASES, Demography < TROPICAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6 **Impact of the COVID-19 pandemic on mortality trends in Japan: a reversal in 2021?**
7

8 *Hirokazu Tanaka**, *Kayo Togawa*, *Kota Katanoda*
9

10
11
12
13 All authors: Division of Surveillance and Policy Evaluation, National Cancer Center Institute for Cancer
14 Control, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
15
16

17
18
19 ***Corresponding author:** Hirokazu Tanaka

20 Division of Surveillance and Policy Evaluation, National Cancer Center Institute for Cancer Control
21 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, JAPAN
22

23 E-mail: hitanak@ncc.go.jp
24

25 Phone: +81335475201
26
27

28 **Figures and Tables:** 3 figures; **Word count:** 1,808 words
29
30

31 **Declarations of interest:** none
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 **Abstract** (249 words)

7 **Objective:** The COVID-19 pandemic led to an increase in mortality in most countries in 2020, deviating
8 from prior decreasing trends. This study investigated long-term mortality trends, focusing on the period of
9 the COVID-19 pandemic in Japan.
10
11

12
13 **Design:** We analysed Japanese age-standardized mortality rates (ASMRs) from 1995 to 2021 using vital
14 statistics.
15
16

17
18 **Main outcome measures:** The cause-specific annual ASMR changes were calculated in comparison with
19 the previous year.
20
21

22 **Results:** There was a general downward trend in overall ASMR for both sexes until 2020 followed by a
23 small increase in 2021. The all-cause ASMR (per 100 000 persons) decreased from 1352.3 to 1328.8 in
24 2020 (-1.74% from 2019), and increased to 1356.3 in 2021 in men (+2.07% from 2020). Similarly, the
25 all-cause ASMR decreased from 746.0 to 722.1 in 2020 (-3.20% from 2019), and increased to 737.9
26 (+2.19% from 2020) in 2021 in women. ASMRs from malignant neoplasms, pneumonia, accidents, and
27 suicide (men only) continued to decrease during the COVID-19 pandemic while the trend of
28 cardiovascular mortality increased in 2021. Analysis of ASMR changes revealed that COVID-19, senility,
29 cardiovascular disease, and 'other causes not classified as major causes' contributed to the all-cause
30 mortality increase in 2021.
31
32
33
34
35
36

37 **Conclusions:** In Japan, the decreasing trend in overall mortality continued in 2020 despite the COVID-19
38 pandemic. However, an approximately 2% mortality increase was observed in 2021, which was
39 attributable to COVID-19, senility, cardiovascular disease, and 'other causes'. The year 2021 may be a
40 turning point of mortality trends in Japan, although continued monitoring is warranted.
41
42
43
44

45 **Funding:** Grants-in-Aid for Cancer Control Policy from the Ministry of Health, Labor, and Welfare,
46 Japan (20EA1017); Japan Agency for Medical Research and Development (AMED: 22ck0106778h0001)
47
48

49 **Keywords:** COVID-19 pandemic; mortality trends; vital statistics; increase in mortality; Japan
50
51
52
53
54
55
56
57
58
59
60

What is already known on this topic

-In most high-income countries, life expectancy in 2020 was shorter than that before 2020 due to the COVID-19 pandemic.

-No nationwide mortality data that discussed the impact of the COVID-19 pandemic on mortality trends was reported in Japan.

What this study adds

-From 1995 to 2020, we found a general downward trend in overall age-standardized mortality rates (ASMRs) for both sexes (except 2011, the year of Great East Japan earthquake) until 2020.

-An increase was observed in 2021 in the annual mortality rate in Japan, though the impact of COVID-19 pandemic on mortality still seems to be limited.

-The analysis of ASMR changes revealed that COVID-19, senility, cardiovascular disease, and 'other causes not classified as major causes' contributed to all-cause mortality increase in 2021.

-Taking the rapidly increasing number of COVID-19 cases in 2022 into consideration, further analysis is warranted for the year 2022, which may reveal increases in deaths from COVID-19 and overall mortality compared to 2020 and 2021.

Introduction

Approximately three years into the pandemic, Japan has been hit by COVID-19. Although the Japanese government did not introduce strict COVID-19 restrictions such as lockdown, people's daily lives were affected, as were the lives of health-care workers since the first declaration of a state of emergency in April 2020. Careful assessment of the impact of the pandemic on population health would aid in the evaluation of efforts during the pandemic and identify lessons, not only for Japan but also globally.

In most high-income countries, life expectancy in 2020 was shorter than before due to the pandemic.¹ For example, reductions in life expectancy in 2020 were observed in Russia, the U.S., Spain, England/Wales, Netherlands, Sweden, and France.² However, in Japan, life expectancy was not shortened in 2020 according to the Japanese Ministry of Health, Labour and Welfare (MHLW),^{1,3} a deviation from the decreasing trend in most countries.¹

Reasons for the prolonged life expectancy in 2020 despite the pandemic are unclear, but one reason could be that Japan did not experience as large a number of COVID-19 cases in that year. However, Japan experienced a six-fold increase in the number of reported cases from 2020 to 2021: 234 109 cases in 2020 and 1 492 874 cases in 2021.⁴ Thus, annual mortality rate in 2021 in Japan may be different from the stable downward trend before 2020. This study aimed to explore the long-term mortality trends and cause-specific contributions during the COVID-19 pandemic in Japan focusing on the years 2020 and 2021.

Methods

To evaluate the trends in the number of COVID-19 cases in Japan, we extracted data on the daily number of reported COVID-19 cases from 16 January 2020 (the first case confirmed) to 28 November 2022 from Japanese government records.⁴ The numbers of deaths (5-year age intervals) between 1995 and 2021 were extracted from the vital statistics (complete deaths record) in Japan managed by MHLW.³ The 2021 complete mortality data was published in September 2022.³ The vital statistics cover all Japanese deaths that occurred in Japan. The relevant population data were also collected from the vital statistics and population census.

We calculated age-standardized mortality rates (ASMRs) for all causes of death combined and cause-specific deaths for major causes from 1995 to 2021 to assess trends in mortality rates. ASMRs were calculated using the 2015 Japan Standard Population. We further calculated the annual percent changes in ASMRs before and during the COVID-19 pandemic (the years of 2020 and 2021). Causes of death (the International Classification of Diseases 10th revision: ICD-10) included: certain infectious and parasitic diseases (A00-B99), malignant neoplasms (C00-C97), heart diseases (I01-I02.0, I05-I09, I20-I25, I27, I30-I52), cerebrovascular diseases (I60-I69), pneumonia (J12-J18), liver disease (K70-K76), senility (R54), accidents (V01-X59), suicide (X60-X84), and COVID-19 (U07). These classifications were based on the leading causes of death reported by the official mortality statistics by MHLW.³

To analyse the contribution of the cause of death to annual all-cause ASMR changes, the cause-specific ASMR changes in comparison with those of the previous year were calculated for six periods from 2015–2016 to 2020–2021.

Patient and public involvement

No patients were involved in this study.

Results

Figure 1 shows trends in the daily number of reported COVID-19 cases in Japan since 16 January 2020. The peak of reported COVID-19 cases was observed in August 2022 (7th COVID-19 wave). The annual number of reported COVID-19 cases increased rapidly from 2020 to 2022.

Figure 2 shows the trends in all-cause ASMRs (per 100 000 persons) between 1995 and 2021. Supplement Table 1 shows the trends in number of deaths in Japan between 1995 and 2021. After the Great East Japan earthquake occurred in 2011, ASMRs continued decreasing until 2020, then increased in 2021 in both sexes. For men, all-cause ASMRs (per 100 000 persons) were 1352.3 in 2019 (-1.69% from 2018), 1328.8 in 2020 (-1.74% from 2019), and 1356.3 in 2021 (+2.07% from 2020). For women, all-cause ASMRs were 746.0 in 2019 (-1.39% from 2018), 722.1 in 2020 (-3.20% from 2019), and 737.9 in 2021 (+2.19% from 2020). Age-specific analyses also showed stable to slightly increased mortality trends during the period of COVID-19 pandemic (Supplement Figure 1). Supplement Figure 2 shows the trends in cause-specific ASMRs between 1995 and 2021. For men, COVID-19 ASMRs were 3.8 in 2020 and 17.5 in 2021. For women, COVID-19 ASMRs were 1.5 in 2020 and 7.7 in 2021. ASMRs from malignant neoplasms, pneumonia, accidents, and suicide (men only) decreased during the COVID-19 pandemic in Japan while the trend of cardiovascular disease (heart disease and cerebrovascular disease combined) increased in 2021. In addition, the trend of suicide in women increased in 2020. Supplement Figure 3 shows trends in malignant neoplasms ASMRs by cancer site. Trends in most malignant neoplasms were decreased or stable, which was not altered compared to the trends before 2020.

Figure 3 shows the cause-specific contribution to annual changes in all-cause ASMR. The analysis of annual ASMR changes revealed that decreases in malignant neoplasms, pneumonia, heart disease, and cerebrovascular diseases continuously contributed to substantial annual mortality reductions for both sexes during 2015–2019; however, the contributions to reduction disappeared for cardiovascular disease from 2020 to 2021. COVID-19 (+13.7 per 100 000 for men and +6.2 per 100 000 for women in comparisons with the previous year) and senility (+7.4 per 100 000 for men and +8.1 per 100,000 for women in comparisons with the previous year) largely contributed to the mortality increases from 2020 to 2021. Also, ‘other causes not classified major causes’ contributed to all-cause mortality increase as well from 2020 to 2021.

Discussion

This is the first study to comprehensively report on mortality analysis in Japan since MHLW published the 2021 complete mortality data for the Japanese population. We found that the numbers of deaths from COVID-19 were 9 732 (1.32% of all deaths) for men and 7 034 (1.00% of all deaths) for women in 2021, a substantial increase from the year 2020 (2 094 deaths for men and 1 372 deaths for women). The number of deaths in the population due to diagnosed COVID-19 was relatively low compared to many other high-income countries.⁵ In both men and women, all-cause ASMR decreased gradually every year from 2011 to 2020 and increased from 2020 to 2021, with a slightly greater decrease in women than in men between 2019 and 2020. In Japan, declining trends in all-cause mortality reversed in 2021 for the first time since the Great East Japan earthquake occurred in 2011.

The mortality trend varied by cause of death. The patterns of mortality change during the COVID-19 pandemic could be classified into the following three categories: (1) stable mortality decline (e.g. certain infectious and parasitic diseases, malignant neoplasms, and pneumonia), (2) stable mortality increase (e.g. senility), and (3) reversal of decreasing mortality trend (heart diseases, cerebrovascular diseases, suicide for women). Considering these changes, a substantial mortality increase from COVID-19 and senility resulted in an all-cause mortality increase in 2021 while malignant neoplasms and pneumonia contributed to mortality declines.

Recorded mortality from malignant neoplasms declined during the COVID-19 pandemic, despite that patients diagnosed with a cancer regardless of COVID-19 status were required to postpone non-urgent surgeries, suspend outpatient visits, and change treatment methods. Indeed, the numbers of cancer diagnoses, the cancer screening, outpatient visits, and surgical procedures in 2020 have been reported to be lower than those before 2019.⁶⁻⁹ Those reports have raised deep concern about potential consequences, such as delays in diagnosis and care, decreased patient survival, and increased population mortality; however, our findings revealed a decrease in 2020 and no obvious change in cancer mortality, at least in 2021. Nevertheless, further monitoring is necessary because the delays in diagnosis and treatment can exert a belated effect on mortality.

We found that the ASMR from cardiovascular disease increased in 2021. The loss of reduction trends of cardiovascular disease partially resulted in increasing all-cause mortality in 2021 for both sexes. This is supported by another study reporting excess deaths from cardiovascular disease from April to May 2021.¹⁰ As a direct pathway, the COVID-19 pandemic may have caused an increase in the prevalence of severe heart disease for the Japanese population because COVID-19 is suggested to be a risk factor for acute myocardial infarction and ischemic stroke.¹¹ In addition, the pandemic might have induced a delay in emergency transport and delay in arrival at hospital, resulting in the loss of timely treatment. This may be an indirect pathway through which mortality reductions of cardiovascular disease stagnated in Japan.

A substantial increase in mortality due to senility has been occurring since the mid-2000s, independent of the pandemic. This can be interpreted as a result of the rapid aging of the Japanese

1
2
3
4
5
6 population. Although we applied age-standardization for mortality analysis, the increase in the absolute
7 number of deaths from senility, especially for the oldest old (85 years and over), resulted in an increase in
8 ASMR. During the pandemic, however, changes in patterns or places of medical care may have resulted
9 in more physicians reporting senility as the cause of death, especially deaths at home. Indeed, excess
10 deaths from senility at home have been observed since May 2020.¹⁰ As such, for the elderly, both direct
11 and indirect death by COVID-19 may be miscoded to senility, which contributed to excess deaths in
12 2021. The sharp increase in deaths by ‘other causes not classified as major causes’ in 2021 (Figure 3) may
13 have occurred by a similar mechanism. Therefore, our findings suggest that senility and ‘other causes not
14 classified as major causes’ may largely represent the excess deaths in Japan during the pandemic. This
15 may also include underdiagnosis and potential misclassification of causes of death.

16
17 We found clear declines in mortality from infectious diseases (excluding COVID-19) and infectious
18 pneumonia since the pandemic began in Japan. This is likely because the countermeasures for COVID-19
19 such as of wearing a mask, hand hygiene, and social distancing prevented these diseases. In addition,
20 clear mortality declines due to accidents were observed probably because fatal traffic accidents decreased
21 due to stay-at-home measures. These are positive outcomes of the COVID-19 measures; however, we
22 identified an increase in suicide rate among women in 2020 and 2021. The increase did not largely impact
23 on all-cause mortality changes for women but this is obviously a negative effect of the COVID-19
24 measures such as restrictions of economic activity (e.g. cancellation of events and shorter business hours
25 for restaurants).^{12,13}

26
27 In conclusion, a sign of increasing mortality was observed in 2021 in the annual mortality rate in
28 Japan, although the impact of the COVID-19 pandemic on mortality in Japan still seems to be limited.
29 The observed increase in mortality was attributable to COVID-19, senility, cardiovascular disease, and
30 ‘other causes not classified as major cause’. Taking the rapidly increasing rate of COVID-19 cases in
31 2022 into consideration, further monitoring is warranted for the year 2022, which may reveal an even
32 larger impact of the pandemic on mortality compared to that for 2020 and 2021.

33 34 **Ethics statements**

35 **Patient consent for publication**

36 Not applicable.

37 **Ethics approval**

38 Ethics approval was not applicable. This study used the vital statistics data from a portal site for Japanese
39 Government Statistics (e-Stat), data at individual level were not used.

40
41 **Authors’ contributions:** All author had full access to all the study data. H.T. was responsible for the
42 integrity of the data, the accuracy of the data analysis, and the drafting of the manuscript. All authors
43 contributed to the concept and design of the study. All authors critically reviewed the manuscript. K.K.
44 supervised the study and provided administrative, technical, and material support.

45
46 **Declaration of interest statement:** The authors have no conflicts of interest directly relevant to the
47 content of this study.

Funding: This research was supported by Grants-in-Aid for Cancer Control Policy from the Ministry of Health, Labor, and Welfare, Japan (20EA1017) and Japan Agency for Medical Research and Development (AMED; Grant Number: 22ck0106778h0001).

Patient and other consents: Not applicable.

Availability of data and materials: Data are available on request.

Acknowledgment: We thank Libby Cone, MD, MA, from DMC Corp.

(www.dmed.co.jp <<http://www.dmed.co.jp/>>) for editing English drafts of this manuscript.

Figure legends

Figure 1. Trends in the daily number of reported COVID-19 cases in Japan since 16 January 2020


Figure 2. Trends in all-cause and cause-specific age-standardized mortality rates between 1995 and 2021

Figure 3. Cause-specific contribution to changes in all-cause age-standardized mortality rates (annual comparisons with previous year): differences in changes in ASMR between 2020 and 2021 were calculated as $(ASMR_{2021} - ASMR_{2020})$ for each cause-specific death, where ASMR=age standardized mortality rate per 100 000 population.


Reference

1. The World Bank. Life expectancy at birth, total (years). <https://data.worldbank.org/indicator/SP.DYN.LE00.IN> Date accessed: December 12, 2022
2. Islam N, Jdanov DA, Shkolnikov VM, et al. Effects of covid-19 pandemic on life expectancy and premature mortality in 2020: time series analysis in 37 countries. *BMJ*. 2021;375:e066768.
3. Ministry of Health, Labour and Welfare. Vital Statistics. <https://www.mhlw.go.jp/english/database/db-hw/vs01.html> Date accessed: December 12, 2022
4. Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19 infections. <https://covid19.mhlw.go.jp/en/> December 12, 2022
5. World Health Organization. WHO coronavirus (COVID-19) dashboard. <https://covid19.who.int> December 12, 2022
6. Ikeda N, Yamamoto H, Taketomi A, et al. The impact of COVID-19 on surgical procedures in Japan: analysis of data from the National Clinical Database. *Surg Today*. 2022;52:22-35.
7. Sato Y, Fujiwara Y, Fukuda N, et al. Changes in Treatment Behavior during the COVID-19 Pandemic among Patients at a Cancer Hospital. *Cancer Cell*. 2021;39:130-131.
8. Toyoda Y, Katanoda K, Ishii K, Yamamoto H, Tabuchi T. Negative impact of the COVID-19 state of emergency on breast cancer screening participation in Japan. *Breast Cancer*. 2021;28:1340-1345.
9. Okuyama A, Watabe M, Makoshi R, Takahashi H, Tsukada Y, Higashi T. Impact of the COVID-19 pandemic on the diagnosis of cancer in Japan: analysis of hospital-based cancer registries. *Jpn J Clin Oncol*. 2022;52:1215-1224.


- 1
2
3
4
5
6 10. Nomura S, Eguchi A, Ghaznavi C, et al. Excess deaths from non-COVID-19-related causes in
7 Japan and 47 prefectures from January 2020 through May 2021 by place of death. *SSM Popul Health*.
8 2022;19:101196.
9
- 10 11. Katsoularis I, Fonseca-Rodriguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of
11 acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case
12 series and matched cohort study. *Lancet*. 2021;398:599-607.
13
- 14 12. Sakamoto H, Ishikane M, Ghaznavi C, Ueda P. Assessment of Suicide in Japan During the
15 COVID-19 Pandemic vs Previous Years. *JAMA Netw Open*. 2021;4:e2037378.
16
- 17 13. Kikuchi K, Anzai T, Takahashi K. The Unusual Increase in Suicides Among Women in Japan
18 During The COVID-19 Pandemic: A Time-Series Analysis until October 2021. *J Epidemiol*. 2022. (in
19 press)
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




39
40
41



(A) Men



(B) Women




Appendix Table 1. Number of deaths in Japan between 1995 and 2021*


Year	Men					Women				
	All-cause	Malignant neoplasms	Heart disease	Cerebrovascular disease	COVID-19	All-cause	Malignant neoplasms	Heart disease	Cerebrovascular disease	COVID-19
1995	501276	159623	69718	69587	-	420863	103399	69488	76965	-
1996	488605	164824	68977	66479	-	407606	106359	69252	73887	-
1997	497796	167076	69776	65790	-	415606	108337	70398	72907	-
1998	512128	172306	71134	65529	-	424356	111615	71986	72290	-
1999	534778	175817	73979	66452	-	447253	114739	77100	72537	-
2000	525903	179140	72156	63127	-	435750	116344	74585	69402	-
2001	528768	181393	72727	63146	-	441563	119265	75565	68710	-
2002	535305	184033	74986	62229	-	447074	120535	77532	68028	-
2003	551746	186912	77989	63274	-	463205	122631	81556	68793	-
2004	557097	193096	77465	61547	-	471505	127262	82160	67508	-
2005	584970	196603	83979	63657	-	498826	129338	89146	69190	-
2006	581370	198052	82811	61348	-	503080	131262	90213	66920	-
2007	592784	202743	83090	60992	-	515550	133725	92449	66049	-
2008	608711	206354	86139	61121	-	533696	136609	95789	65902	-
2009	609042	206352	85543	59293	-	532823	137753	95202	63057	-
2010	633700	211435	88803	60186	-	563312	142064	100557	63275	-
2011	656540	213190	91298	59616	-	596526	144115	103628	64251	-
2012	655526	215110	92976	58625	-	600833	145853	105860	62977	-
2013	658684	216975	91445	56718	-	609752	147897	105278	61629	-
2014	660334	218397	92278	54995	-	612670	149706	104647	59212	-
2015	666707	219508	92142	53576	-	623737	150838	103971	58397	-
2016	674946	219846	93453	52718	-	633212	153242	104617	56635	-
2017	690770	220416	96330	53198	-	649797	152949	108538	56698	-
2018	699138	218625	98035	52398	-	663332	154959	110186	55788	-
2019	707421	220339	98210	51768	-	673672	156086	109504	54784	-
2020	706834	220989	99304	50390	2094	665921	157396	106292	52588	1372
2021	738141	222467	103700	51594	9732	701715	159038	111010	53001	7034

*Malignant neoplasms (ICD-10: C00-C97); Heart diseases (I01-I02.0, I05-I09, I20-I25, I27, I30-I52); Cerebrovascular diseases (I60-I69); COVID-19 (U07)


(A) All cause (men, 0-44 years)




(B) All cause (women, 0-44 years)




(C) All cause (men, 45-69 years)




(D) All cause (women, 45-69 years)



(E) All cause (men, 70-95 years and over)




(F) All cause (women, 70-95 years and over)




Appendix Figure 1. Trends in crude mortality rate by five-year age groups between 1995 and 2021


(A) Certain infectious and parasitic diseases (A00-B99)




(B) Malignant neoplasms (C00-96)




(C) Heart diseases (I05-09, I20-25, I27, I30-51)




(D) Cerebrovascular diseases (I60-69)




(E) Pneumonia & Bronchitis (J12-18)




(F) Liver disease (K70-76)




(G) Senility (R54)




(H) Accidents (V01-X59)



(I) Suicide (X60-84)




(J) COVID-19 (U07)




Appendix Figure 2. Trends in cause-specific age-standardized mortality rates by cancer site between 1995 and 2021


(A) Oral cavity and pharynx (C00-14)




(B) Esophagus (C15)




(C) Stomach (C16)




(D) Colon (C18)




(E) Rectum (C19-20)




(F) Liver (C22)




(G) Gallbladder and bile ducts (C23-24)




(H) Pancreas (C25)




(I) Larynx (C32)




(J) Lung, trachea (C33-34)




(K) Skin (C43-44)




(L) Breast (C50)




(M) Uterus (C53-55)




(N) Ovary (C56)




(O) Prostate (C61)




(P) Bladder (C67)




(Q) Brain, nervous system (C70-72)



(R) Malignant lymphoma (C81-85, C96)



(S) Leukemia (C91-95)



Appendix Figure 3. Trends in cancer age-standardized mortality rates by cancer site between 1995 and 2021

BMJ Open

Impact of the COVID-19 pandemic on mortality trends in Japan: a reversal in 2021? A descriptive analysis of national mortality data, 1995-2021

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-071785.R1
Article Type:	Original research
Date Submitted by the Author:	21-Jun-2023
Complete List of Authors:	Tanaka, Hirokazu; National Cancer Center Japan, Division of Surveillance and Policy Evaluation Togawa, Kayo; National Cancer Center Japan Katanoda, Kota; National Cancer Center Japan
Primary Subject Heading:	Public health
Secondary Subject Heading:	Epidemiology
Keywords:	COVID-19, Epidemiology < TROPICAL MEDICINE, Public health < INFECTIOUS DISEASES, Demography < TROPICAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6 **1 Impact of the COVID-19 pandemic on mortality trends in Japan: a reversal in 2021? A descriptive**
7 **2 analysis of national mortality data, 1995-2021**
8
9 **3**

10 **4** *Hirokazu Tanaka**, *Kayo Togawa*, *Kota Katanoda*
11
12 **5**
13 **6**

14 **7** All authors: Division of Population Data Science, National Cancer Center Institute for Cancer Control, 5-
15
16 **8** 1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
17
18 **9**

19 **10**
20
21 **11** ***Corresponding author:** Hirokazu Tanaka
22

23 **12** Division of Population Data Science, National Cancer Center Institute for Cancer Control
24

25 **13** 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, JAPAN
26

27 **14** E-mail: hitanak@ncc.go.jp
28

29 **15** Phone: +81335475201
30

31 **16**
32
33 **17** **Figures and Tables:** 4 figures; **Word count:** 2,012 words
34

35 **18**
36
37 **19** **Declarations of interest:** none
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 37 **Abstract** (266 words)

7 38 **Objective:** The COVID-19 pandemic led to an increase in mortality in most countries in 2020, deviating
8
9 39 from prior decreasing trends. In Japan, however, mortality was suggested to decrease in 2020. This study
10 40 investigated long-term mortality trends and cause-specific contributions, focusing on the period of the
11 41 COVID-19 pandemic in Japan.
12 42

13
14 43 **Design:** We analysed Japanese age-standardized mortality rates (ASMRs) from 1995 to 2021 using vital
15 44 statistics.
16 45

17
18 46 **Main outcome measures:** The cause-specific annual ASMR changes were calculated in comparison with
19 47 the previous year over the abovementioned period.
20 48

21
22 49 **Results:** There was a general downward trend in overall ASMR for both sexes until 2020 followed by a
23 50 small increase in 2021. In men, the all-cause ASMR (per 100,000 persons) decreased from 1352.3 to
24 51 1328.8 in 2020 (−1.74% from 2019), and increased to 1356.3 in 2021 in men (+2.07% from 2020). In
25 52 women, the all-cause ASMR decreased from 746.0 to 722.1 in 2020 (−3.20% from 2019), and increased
26 53 to 737.9 (+2.19% from 2020) in 2021. ASMRs from malignant neoplasms, pneumonia, accidents, and
27 54 suicide (men only) continued to decrease during the COVID-19 pandemic while the trend of
28 55 cardiovascular mortality increased in 2021. Analysis of ASMR changes revealed that COVID-19, senility,
29 56 cardiovascular disease, and ‘other causes not classified as major causes’ contributed to the all-cause
30 57 mortality increase in 2021.
31 58

32
33 59 **Conclusions:** In Japan, the decreasing trend in overall mortality continued in 2020 despite the COVID-19
34 60 pandemic. However, approximately 2% mortality increase was observed in 2021, which was attributable
35 61 to COVID-19, senility, cardiovascular disease, and ‘other causes’. The year 2021 was a turning point of
36 62 mortality trends in Japan, although continued monitoring is warranted.
37 63

38
39 64 **Funding:** Grants-in-Aid for Cancer Control Policy from the Ministry of Health, Labour, and Welfare,
40 65 Japan (20EA1017); Japan Agency for Medical Research and Development (AMED: 22ck0106778h0001)
41 66

42
43 67 **Keywords:** COVID-19 pandemic; mortality trends; vital statistics; increase in mortality; Japan
44 68
45 69
46 70
47 71
48 72

1
2
3
4
5
6 **73 Strengths and limitations of this study**

- 7 74 • This is the first study to report comprehensively on mortality in Japan since the Ministry of Health,
8 75 Labour, and Welfare published the 2021 complete mortality data for the Japanese population.
9
10 76 • From 1995 to 2020, we found a general downward trend in overall age-standardized mortality rates
11 77 (ASMRs) for both sexes (except 2011, the year of the Great East Japan Earthquake) until 2020.
12
13 78 • An increase was observed in 2021 in the annual mortality rate, though the impact of COVID-19
14 79 pandemic on mortality still seems to be limited.
15
16 80 • The analysis of ASMR changes revealed that COVID-19, senility, cardiovascular disease, and ‘other
17 81 causes not classified as major causes’ contributed to all-cause mortality increase in 2021.
18
19 82 • The mortality increase in 2021 may be associated with the increase of COVID-19 cases; however,
20 83 further analysis is needed to clarify the quantitative impact of the increase, such as ‘excess deaths’.
21
22 84
23 85
24 86
25 87
26 88
27 89
28 90
29 91
30 92
31 93
32 94
33 95
34 96
35 97
36 98
37 99
38 100
39 101
40 102
41 103
42 104
43 105
44 106
45 107
46 108
47
48
49
50
51
52
53
54
55
56
57
58
59
60

109 Introduction

110 Approximately three years into the pandemic, the impact of COVID-19 on Japan continues to increase.
111 Although the Japanese government did not introduce strict COVID-19 restrictions such as lockdown,
112 people's daily lives were affected, as were the lives of health-care workers since the first declaration of a
113 state of emergency in April 2020. To date, however, no nationwide mortality data that discuss the impact
114 of the COVID-19 pandemic on mortality trends have been reported in Japan. Careful assessment of the
115 impact of the pandemic on population health would aid in the evaluation of efforts during the pandemic
116 and identify lessons, not only for Japan but also globally.

117 In most high-income countries, life expectancy in 2020 was shorter than that before, attributable to
118 both the direct and indirect effects of COVID-19.¹ For example, reductions in life expectancy in 2020
119 were observed in Russia, the U.S., Spain, England/Wales, Netherlands, Sweden, and France.² However,
120 in Japan, life expectancy was not shortened in 2020 according to the Japanese Ministry of Health, Labour
121 and Welfare (MHLW),^{1,3} a deviation from the decreasing trend in most countries.¹

122 Reasons for the prolonged life expectancy in 2020 despite the pandemic are unclear. One reason
123 could be that Japan did not experience as large a number of COVID-19 cases that year as other countries.
124 However, Japan experienced a six-fold increase in the number of reported cases from 2020 to 2021: 234
125 109 cases in 2020 and 1 492 874 cases in 2021.⁴ Thus, annual mortality rate in 2021 in Japan may differ
126 from the stable downward trend seen before 2020. This study aimed to explore the long-term mortality
127 trends and cause-specific contributions during the COVID-19 pandemic in Japan, focusing on the years
128 2020 and 2021.

130 Methods

131 We illustrated changes in life expectancy between 2019 and 2020 for selected countries, including Japan,
132 using data extracted from the World Development Indicators managed by the World Bank.¹ To evaluate
133 the trends in the number of COVID-19 cases in Japan, we extracted data on the daily number of reported
134 COVID-19 cases from 16 January 2020 (the first case confirmed) to 1 January 2023 from Japanese
135 government records.⁴ The numbers of deaths (5-year age intervals) between 1995 and 2021 were
136 extracted from the vital statistics (complete deaths record) in Japan managed by MHLW.³ The 2021
137 complete mortality data were published in September 2022.³ The vital statistics cover all Japanese deaths
138 that occurred in Japan. The relevant population data were also collected from the vital statistics and
139 population census.

140 We calculated age-standardized mortality rates (ASMRs) for all causes of death combined and
141 cause-specific deaths for major causes from 1995 to 2021 to assess trends in mortality rates. ASMRs were
142 calculated using the 2015 Japan Standard Population.⁵ We further calculated the annual percent changes
143 in ASMRs before and during the early part of the COVID-19 pandemic (2020 and 2021). Causes of death
144 (the International Classification of Diseases 10th revision: ICD-10) included: certain infectious and

1
2
3
4
5
6 145 parasitic diseases (A00-B99), malignant neoplasms (C00-C97), heart diseases (I01-I02.0, I05-I09, I20-
7 146 I25, I27, I30-I52), cerebrovascular diseases (I60-I69), pneumonia (J12-J18), liver disease (K70-K76),
8 147 senility (R54), accidents (V01-X59), suicide (X60-X84), and COVID-19 (U07). These classifications
9 148 were based on the leading causes of death reported by the official mortality statistics from MHLW.³
10 149 MHLW follows the algorithm for classifying the causes of death based on ICD-10.

11
12
13 150 To analyse the contribution of the cause of death to annual all-cause ASMR changes, the cause-
14 151 specific ASMR changes in comparison with those of the previous year were calculated for six periods
15 152 from 2015–2016 to 2020–2021.

16 153

17 154 **Patient and public involvement**

18
19 155 Actual patients were not involved in this study of data.

20 156

21 157 **Results**

22 158 Figure 1 shows Japan was one of the countries where life expectancy was prolonged in 2020 despite
23 159 having shortened in many high-income countries such as the U.S. and France. Figure 2 shows trends in
24 160 the daily number of reported COVID-19 cases in Japan since 16 January 2020. The peak of reported
25 161 COVID-19 cases was observed in August 2022 (7th COVID-19 wave). While the absolute number of
26 162 COVID-19 cases was very small in 2020, the annual number of reported COVID-19 cases increased
27 163 rapidly in 2021 and 2022.

28 164 Figure 3 shows the trends in all-cause ASMRs (per 100 000 persons) between 1995 and 2021.
29 165 Supplement Table 1 shows the trends in number of deaths in Japan between 1995 and 2021. After the
30 166 Great East Japan Earthquake occurred in 2011, ASMRs continued decreasing until 2020, then increased
31 167 in 2021 in both sexes. For men, all-cause ASMRs (per 100 000 persons) were 1352.3 in 2019 (-1.69%
32 168 from 2018), 1328.8 in 2020 (-1.74% from 2019), and 1356.3 in 2021 (+2.07% from 2020). For women,
33 169 all-cause ASMRs were 746.0 in 2019 (-1.39% from 2018), 722.1 in 2020 (-3.20% from 2019), and 737.9
34 170 in 2021 (+2.19% from 2020). Age-specific analyses also showed stable to slightly increased mortality
35 171 trends during the period of COVID-19 pandemic (Supplement Figure 1). Supplement Figure 2 shows the
36 172 trends in cause-specific ASMRs between 1995 and 2021. For men, COVID-19 ASMRs were 3.8 in 2020
37 173 and 17.5 in 2021. For women, COVID-19 ASMRs were 1.5 in 2020 and 7.7 in 2021. ASMRs from
38 174 malignant neoplasms, pneumonia, accidents, and suicide (men only) decreased during the COVID-19
39 175 pandemic in Japan while the trend of cardiovascular disease (heart disease and cerebrovascular disease
40 176 combined) increased in 2021. In addition, the trend of suicide in women increased in 2020. Supplement
41 177 Figure 3 shows trends in malignant neoplasms ASMRs by cancer site. Trends in most malignant
42 178 neoplasms were decreased or stable, which was not altered compared to the trends before 2020.

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57 179 Figure 4 shows the cause-specific contribution to annual changes in all-cause ASMR. The analysis
58 180 of annual ASMR changes revealed that decreases in malignant neoplasms, pneumonia, heart disease, and

1
2
3
4
5
6 181 cerebrovascular diseases continuously contributed to substantial annual mortality reductions for both
7 182 sexes during 2015–2019; however, the contributions to reduction disappeared for cardiovascular disease
8 183 from 2020 to 2021. COVID-19 (+13.7 per 100 000 for men and +6.2 per 100 000 for women in
9 184 comparisons with the previous year) and senility (+7.4 per 100 000 for men and +8.1 per 100,000 for
10 185 women in comparisons with the previous year) largely contributed to the mortality increases from 2020 to
11 186 2021. Also, ‘other causes not classified major causes’ contributed to all-cause mortality increase as well
12 187 from 2020 to 2021.
13
14
15
16
17

188

189 **Discussion**

190 This is the first study to comprehensively report on mortality analysis in Japan since MHLW published
21 191 the 2021 complete mortality data for the Japanese population. We found that the numbers of deaths from
22 192 COVID-19 were 9 732 (1.32% of all deaths) for men and 7 034 (1.00% of all deaths) for women in 2021,
23 193 a substantial increase from the year 2020 (2 094 deaths for men and 1 372 deaths for women). The
24 194 number of deaths in the population due to diagnosed COVID-19 was relatively low compared to many
25 195 other high-income countries.⁶ In both men and women, all-cause ASMR decreased gradually every year
26 196 from 2011 to 2020 and increased from 2020 to 2021, with a slightly greater decrease in women than in
27 197 men between 2019 and 2020. In Japan, declining trends in all-cause mortality reversed in 2021 for the
28 198 first time since the Great East Japan Earthquake occurred in 2011.

29
30
31
32
33 199 The mortality trend varied by cause of death. The patterns of mortality change during the COVID-19
34 200 pandemic could be classified into the following three categories: (1) stable mortality decline (e.g. certain
35 201 infectious and parasitic diseases, malignant neoplasms, and pneumonia), (2) stable mortality increase (e.g.
36 202 senility), and (3) reversal of decreasing mortality trend (heart diseases, cerebrovascular diseases, suicide
37 203 for women). Considering these changes, a substantial mortality increase from COVID-19 and senility
38 204 resulted in an all-cause mortality increase in 2021 while malignant neoplasms and pneumonia contributed
39 205 to mortality declines.

40
41
42
43 206 Recorded mortality from malignant neoplasms declined during the COVID-19 pandemic, despite
44 207 that patients diagnosed with a cancer regardless of COVID-19 status were required to postpone non-
45 208 urgent surgeries, suspend outpatient visits, and change treatment methods. Indeed, the numbers of cancer
46 209 diagnoses, the cancer screening, outpatient visits, and surgical procedures in 2020 have been reported to
47 210 be lower than those before 2019.⁷⁻¹⁰ Those reports have raised deep concern about potential
48 211 consequences, such as delays in diagnosis and care, decreased patient survival, and increased population
49 212 mortality; however, our findings revealed a decrease in 2020 and no obvious change in cancer mortality,
50 213 at least in 2021. Nevertheless, further monitoring is necessary because the delays in diagnosis and
51 214 treatment can exert a belated effect on mortality.

52
53
54
55
56 215 We found that the ASMR from cardiovascular disease increased in 2021. The loss of reduction
57 216 trends of cardiovascular disease partially resulted in increasing all-cause mortality in 2021 for both sexes.
58
59
60

1
2
3
4
5
6 217 This is supported by another study reporting excess deaths from cardiovascular disease from April to May
7 218 2021.¹¹ As a direct pathway, the COVID-19 pandemic may have caused an increase in the prevalence of
8
9 219 severe heart disease for the Japanese population because COVID-19 is suggested to be a risk factor for
10 220 acute myocardial infarction and ischemic stroke.¹² In addition, the pandemic might have induced a delay
11 221 in emergency transport and delay in arrival at hospital, resulting in the loss of timely treatment. This may
12
13 222 be an indirect pathway through which mortality reductions of cardiovascular disease stagnated in Japan.

14 223 A substantial increase in mortality due to senility has been occurring since the mid-2000s,
15
16 224 independent of the pandemic. This can be interpreted as a result of the rapid aging of the Japanese
17
18 225 population. Although we applied age-standardization for mortality analysis, the increase in the absolute
19 226 number of deaths from senility, especially for the oldest old (85 years and over), resulted in an increase in
20 227 ASMR. During the pandemic, however, changes in patterns or places of medical care may have resulted
21
22 228 in more physicians reporting senility as the cause of death, especially deaths at home. Indeed, excess
23
24 229 deaths from senility at home have been observed since May 2020.¹¹ As such, for the elderly, both direct
25 230 and indirect death by COVID-19 may be miscoded to senility, which contributed to excess deaths in
26
27 231 2021. The sharp increase in deaths by ‘other causes not classified as major causes’ in 2021 (Figure 3) may
28 232 have occurred by a similar mechanism. Therefore, our findings suggest that senility and ‘other causes not
29
30 233 classified as major causes’ may largely represent the excess deaths in Japan during the pandemic. This
31 234 may also include underdiagnosis and potential misclassification of causes of death.

32 235 We found clear declines in mortality from infectious diseases (excluding COVID-19) and infectious
33
34 236 pneumonia since the pandemic began in Japan. This is likely because the countermeasures for COVID-19
35
36 237 such as wearing a mask, hand hygiene, and social distancing prevented these diseases. In addition, clear
37 238 mortality declines due to accidents were observed probably because fatal traffic accidents decreased due
38
39 239 to stay-at-home measures. These are positive outcomes of the COVID-19 measures; however, we
40 240 identified an increase in suicide rate among women in 2020 and 2021. The increase did not largely impact
41 241 on all-cause mortality changes for women but this is obviously a negative effect of the COVID-19
42
43 242 measures such as restrictions of economic activity (e.g. cancellation of events and shorter business hours
44
45 243 for restaurants).^{13,14}

46 244 This study is a descriptive analysis of national mortality data and should accordingly be interpreted
47
48 245 with caution. Our findings suggest that the mortality increase in 2021 may be associated with the increase
49 246 in COVID-19 cases; however, further analysis is needed to clarify the quantitative impact such as ‘excess
50
51 247 deaths’. Also, long-term monitoring is necessary from 2022 onwards, especially for deaths from chronic
52
53 248 diseases that may have long-term effects by changes in lifestyle and medical care.

54 249 In conclusion, a sign of increasing mortality was observed in 2021 in the annual mortality rate in
55
56 250 Japan, although the impact of the COVID-19 pandemic on mortality in Japan still seems to be limited.
57
58 251 The observed increase in mortality was attributable to COVID-19, senility, cardiovascular disease, and
59
60 252 ‘other causes not classified as major cause’. Taking the rapidly increasing rate of COVID-19 cases in

2022 into consideration, further monitoring is warranted for the year 2022, which may reveal a larger impact of the pandemic on mortality compared to that for 2020 and 2021.

255

256 **Ethics statements**

257 **Patient consent for publication**

258 Not applicable.

259 **Ethics approval**

260 Ethics approval was not applicable.

261 **Data availability**

262 This study used the vital statistics data from a portal site for Japanese Government Statistics (e-Stat: <https://www.e-stat.go.jp/>), and data at an individual level were not used.

264

265 **Authors' contributions:** All author had full access to all the study data. H.T. was responsible for the integrity of the data, the accuracy of the data analysis, and the drafting of the manuscript. All authors contributed to the concept and design of the study. All authors critically reviewed the manuscript. K.K. supervised the study and provided administrative, technical, and material support.

269 **Declaration of interest statement:** The authors have no conflicts of interest directly relevant to the content of this study.

271 **Funding:** This research was supported by Grants-in-Aid for Cancer Control Policy from the Ministry of Health, Labour, and Welfare, Japan (20EA1017) and Japan Agency for Medical Research and Development (AMED; Grant Number: 22ck0106778h0001).

274 **Patient and other consents:** Not applicable.

275 **Availability of data and materials:** Data are available on request.

276 **Acknowledgment:** We thank Libby Cone, MD, MA, from Dmed (www.dmed.co.jp <<http://www.dmed.co.jp/>>) for editing English drafts of this manuscript.

278

279 **Figure legends**

280 **Figure 1.** Changes in life expectancy between 2019 and 2020 for selected countries for both sexes

281 **Figure 2.** Trends in the daily number of reported COVID-19 cases in Japan since 16 January 2020

282 **Figure 3.** Trends in all-cause and cause-specific age-standardized mortality rates between 1995 and 2021


283 **Figure 4.** Cause-specific contribution to changes in all-cause age-standardized mortality rates (annual comparisons with previous year): differences in changes in ASMR between 2020 and 2021 were calculated as $(ASMR_{2021} - ASMR_{2020})$ for each cause-specific death, where ASMR=age standardized mortality rate per 100 000 population.

287


288 **Reference**


- 1
2
3
4
5
6 289 1. The World Bank. Life expectancy at birth, total (years).
7 290 <https://data.worldbank.org/indicator/SP.DYN.LE00.IN> Date accessed: December 12, 2022
- 8
9 291 2. Islam N, Jdanov DA, Shkolnikov VM, et al. Effects of covid-19 pandemic on life expectancy
10 292 and premature mortality in 2020: time series analysis in 37 countries. *BMJ*. 2021;375:e066768.
- 11
12 293 3. Ministry of Health, Labour and Welfare. Vital Statistics.
13 294 <https://www.mhlw.go.jp/english/database/db-hw/vs01.html> Date accessed: December 12, 2022
- 14
15 295 4. Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19
16 296 infections. <https://covid19.mhlw.go.jp/en/> December 12, 2022
- 17
18 297 5. Tanaka H, Tanaka S, Togawa K, Katanoda K. Practical implications of the update to the 2015
19 298 Japan Standard Population: mortality archive from 1950 to 2020 in Japan. *J Epidemiol*. (in press)
- 20
21 299 6. World Health Organization. WHO coronavirus (COVID-19) dashboard.
22 300 <https://covid19.who.int> December 12, 2022
- 23
24 301 7. Ikeda N, Yamamoto H, Taketomi A, et al. The impact of COVID-19 on surgical procedures in
25 302 Japan: analysis of data from the National Clinical Database. *Surg Today*. 2022;52:22-35.
- 26
27 303 8. Sato Y, Fujiwara Y, Fukuda N, et al. Changes in Treatment Behavior during the COVID-19
28 304 Pandemic among Patients at a Cancer Hospital. *Cancer Cell*. 2021;39:130-131.
- 29
30 305 9. Toyoda Y, Katanoda K, Ishii K, Yamamoto H, Tabuchi T. Negative impact of the COVID-19
31 306 state of emergency on breast cancer screening participation in Japan. *Breast Cancer*. 2021;28:1340-1345.
- 32
33 307 10. Okuyama A, Watabe M, Makoshi R, Takahashi H, Tsukada Y, Higashi T. Impact of the
34 308 COVID-19 pandemic on the diagnosis of cancer in Japan: analysis of hospital-based cancer registries. *Jpn*
35 309 *J Clin Oncol*. 2022;52:1215-1224.
- 36
37 310 11. Nomura S, Eguchi A, Ghaznavi C, et al. Excess deaths from non-COVID-19-related causes in
38 311 Japan and 47 prefectures from January 2020 through May 2021 by place of death. *SSM Popul Health*.
39 312 2022;19:101196.
- 40
41 313 12. Katsoularis I, Fonseca-Rodriguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of
42 314 acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case
43 315 series and matched cohort study. *Lancet*. 2021;398:599-607.
- 44
45 316 13. Sakamoto H, Ishikane M, Ghaznavi C, Ueda P. Assessment of Suicide in Japan During the
46 317 COVID-19 Pandemic vs Previous Years. *JAMA Netw Open*. 2021;4:e2037378.
- 47
48 318 14. Kikuchi K, Anzai T, Takahashi K. The Unusual Increase in Suicides Among Women in Japan
49 319 During The COVID-19 Pandemic: A Time-Series Analysis until October 2021. *J Epidemiol*. 2022. (in
50 320 press)

Changes in life expectancy between 2019 and 2020, years




27
28
29
30
31
32
33
34
35
36






(A) Men



(B) Women




Appendix Table 1. Number of deaths in Japan between 1995 and 2021*


Year	Men					Women				
	All-cause	Malignant neoplasms	Heart disease	Cerebrovascular disease	COVID-19	All-cause	Malignant neoplasms	Heart disease	Cerebrovascular disease	COVID-19
1995	501276	159623	69718	69587	-	420863	103399	69488	76965	-
1996	488605	164824	68977	66479	-	407606	106359	69252	73887	-
1997	497796	167076	69776	65790	-	415606	108337	70398	72907	-
1998	512128	172306	71134	65529	-	424356	111615	71986	72290	-
1999	534778	175817	73979	66452	-	447253	114739	77100	72537	-
2000	525903	179140	72156	63127	-	435750	116344	74585	69402	-
2001	528768	181393	72727	63146	-	441563	119265	75565	68710	-
2002	535305	184033	74986	62229	-	447074	120535	77532	68028	-
2003	551746	186912	77989	63274	-	463205	122631	81556	68793	-
2004	557097	193096	77465	61547	-	471505	127262	82160	67508	-
2005	584970	196603	83979	63657	-	498826	129338	89146	69190	-
2006	581370	198052	82811	61348	-	503080	131262	90213	66920	-
2007	592784	202743	83090	60992	-	515550	133725	92449	66049	-
2008	608711	206354	86139	61121	-	533696	136609	95789	65902	-
2009	609042	206352	85543	59293	-	532823	137753	95202	63057	-
2010	633700	211435	88803	60186	-	563312	142064	100557	63275	-
2011	656540	213190	91298	59616	-	596526	144115	103628	64251	-
2012	655526	215110	92976	58625	-	600833	145853	105860	62977	-
2013	658684	216975	91445	56718	-	609752	147897	105278	61629	-
2014	660334	218397	92278	54995	-	612670	149706	104647	59212	-
2015	666707	219508	92142	53576	-	623737	150838	103971	58397	-
2016	674946	219846	93453	52718	-	633212	153242	104617	56635	-
2017	690770	220416	96330	53198	-	649797	152949	108538	56698	-
2018	699138	218625	98035	52398	-	663332	154959	110186	55788	-
2019	707421	220339	98210	51768	-	673672	156086	109504	54784	-
2020	706834	220989	99304	50390	2094	665921	157396	106292	52588	1372
2021	738141	222467	103700	51594	9732	701715	159038	111010	53001	7034

*Malignant neoplasms (ICD-10: C00-C97); Heart diseases (I01-I02.0, I05-I09, I20-I25, I27, I30-I52); Cerebrovascular diseases (I60-I69); COVID-19 (U07)


(A) All cause (men, 0-44 years)




(B) All cause (women, 0-44 years)




(C) All cause (men, 45-69 years)




(D) All cause (women, 45-69 years)



(E) All cause (men, 70-95 years and over)




(F) All cause (women, 70-95 years and over)




Appendix Figure 1. Trends in crude mortality rate by five-year age groups between 1995 and 2021


(A) Certain infectious and parasitic diseases (A00-B99)




(B) Malignant neoplasms (C00-96)




(C) Heart diseases (I05-09, I20-25, I27, I30-51)




(D) Cerebrovascular diseases (I60-69)




(E) Pneumonia & Bronchitis (J12-18)




(F) Liver disease (K70-76)




(G) Senility (R54)




(H) Accidents (V01-X59)



(I) Suicide (X60-84)




(J) COVID-19 (U07)




Appendix Figure 2. Trends in cause-specific age-standardized mortality rates by cancer site between 1995 and 2021


(A) Oral cavity and pharynx (C00-14)




(B) Esophagus (C15)




(C) Stomach (C16)




(D) Colon (C18)




(E) Rectum (C19-20)




(F) Liver (C22)




(G) Gallbladder and bile ducts (C23-24)




(H) Pancreas (C25)




(I) Larynx (C32)




(J) Lung, trachea (C33-34)




(K) Skin (C43-44)




(L) Breast (C50)




(M) Uterus (C53-55)




(N) Ovary (C56)




(O) Prostate (C61)




(P) Bladder (C67)



(Q) Brain, nervous system (C70-72)




(R) Malignant lymphoma (C81-85, C96)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(S) Leukemia (C91-95)



Appendix Figure 3. Trends in cancer age-standardized mortality rates by cancer site between 1995 and 2021

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found		RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	Title (line 1-2), abstract (line 38-44)
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported			Introduction (line 109-121)
Objectives	3	State specific objectives, including any prespecified hypotheses			Introduction (line 122-128)
Methods					
Study Design	4	Present key elements of study design early in the paper			Method (line 131-139)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection			Method (line 131-139)

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27</p> <p>Participants</p>	<p>6</p>	<p>(a) <i>Cohort study</i> - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>		<p>RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	<p>Method (line 131-139)</p>
<p>28 29 30 31 32 33 34</p> <p>Variables</p>	<p>7</p>	<p>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.</p>		<p>RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.</p>	<p>Method (line 140-149)</p>
<p>35 36 37 38 39 40 41 42</p> <p>Data sources/ measurement</p>	<p>8</p>	<p>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</p>			<p>Method (line 131-139)</p>

1 2 3 4	Bias	9	Describe any efforts to address potential sources of bias		None.
5 6 7 8 9	Study size	10	Explain how the study size was arrived at		None.
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why		Method (line 140-149)
35 36 37 38 39 40 41 42 43 44 45 46 47	Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses		Method (line 140-149)
	Data access and cleaning methods		..	RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.	Data availability (line 261-263)

				RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	
Linkage		..		RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	None.
Results					
Participants	13	(a) Report the numbers of individuals at each stage of the study (<i>e.g.</i> , numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram		RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Results (line 158-163)
Descriptive data	14	(a) Give characteristics of study participants (<i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i> , average and total amount)			Results (line 158-163)
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report numbers in each exposure			Results (line 164-178)

		category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures			
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period			Results (line 164-187)
Other analyses	17	Report other analyses done— e.g., analyses of subgroups and interactions, and sensitivity analyses			None.
Discussion					
Key results	18	Summarise key results with reference to study objectives			Discussion (line 190-198)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias		RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Discussion (line 244-248)
Interpretation	20	Give a cautious overall interpretation of results considering objectives,			Discussion (line 199-243)

		limitations, multiplicity of analyses, results from similar studies, and other relevant evidence			
Generalisability	21	Discuss the generalisability (external validity) of the study results			None.
Other Information					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based			Funding (line 271-273)
Accessibility of protocol, raw data, and programming code		..		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	None.

*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.

BMJ Open

Impact of the COVID-19 pandemic on mortality trends in Japan: a reversal in 2021? A descriptive analysis of national mortality data, 1995-2021

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-071785.R2
Article Type:	Original research
Date Submitted by the Author:	20-Jul-2023
Complete List of Authors:	Tanaka, Hirokazu; National Cancer Center Japan, Division of Surveillance and Policy Evaluation Togawa, Kayo; National Cancer Center Japan Katanoda, Kota; National Cancer Center Japan
Primary Subject Heading:	Public health
Secondary Subject Heading:	Epidemiology
Keywords:	COVID-19, Epidemiology < TROPICAL MEDICINE, Public health < INFECTIOUS DISEASES, Demography < TROPICAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6 **1 Impact of the COVID-19 pandemic on mortality trends in Japan: a reversal in 2021? A descriptive**
7 **2 analysis of national mortality data, 1995-2021**
8
9 **3**

10 **4** *Hirokazu Tanaka**, *Kayo Togawa*, *Kota Katanoda*
11
12 **5**
13 **6**

14 **7** All authors: Division of Population Data Science, National Cancer Center Institute for Cancer Control, 5-
15
16 **8** 1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
17
18 **9**

19 **10**
20
21 **11** ***Corresponding author:** Hirokazu Tanaka
22

23 **12** Division of Population Data Science, National Cancer Center Institute for Cancer Control
24

25 **13** 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, JAPAN
26

27 **14** E-mail: hitanak@ncc.go.jp
28

29 **15** Phone: +81335475201
30

31 **16**
32
33 **17** **Figures and Tables:** 4 figures; **Word count:** 2,012 words
34

35 **18**
36
37 **19** **Declarations of interest:** none
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 37 **Abstract** (266 words)

7 38 **Objective:** The COVID-19 pandemic led to an increase in mortality in most countries in 2020, deviating
8
9 39 from prior decreasing trends. In Japan, however, mortality was suggested to decrease in 2020. This study
10 40 investigated long-term mortality trends and cause-specific contributions, focusing on the period of the
11 41 COVID-19 pandemic in Japan.
12 42

13 43 **Design:** We analysed Japanese age-standardized mortality rates (ASMRs) from 1995 to 2021 using vital
14 44 statistics.
15 45

16 46 **Main outcome measures:** The cause-specific annual ASMR changes were calculated in comparison with
17 47 the previous year over the abovementioned period.
18 48

19 49 **Results:** There was a general downward trend in overall ASMR for both sexes until 2020 followed by a
20 50 small increase in 2021. In men, the all-cause ASMR (per 100,000 persons) decreased from 1352.3 to
21 51 1328.8 in 2020 (−1.74% from 2019), and increased to 1356.3 in 2021 in men (+2.07% from 2020). In
22 52 women, the all-cause ASMR decreased from 746.0 to 722.1 in 2020 (−3.20% from 2019), and increased
23 53 to 737.9 (+2.19% from 2020) in 2021. ASMRs from malignant neoplasms, pneumonia, accidents, and
24 54 suicide (men only) continued to decrease during the COVID-19 pandemic while the trend of
25 55 cardiovascular mortality increased in 2021. Analysis of ASMR changes revealed that COVID-19, senility,
26 56 cardiovascular disease, and ‘other causes not classified as major causes’ contributed to the all-cause
27 57 mortality increase in 2021.
28 58

29 59 **Conclusions:** In Japan, the decreasing trend in overall mortality continued in 2020 despite the COVID-19
30 60 pandemic. However, approximately 2% mortality increase was observed in 2021, which was attributable
31 61 to COVID-19, senility, cardiovascular disease, and ‘other causes’. The year 2021 was a turning point of
32 62 mortality trends in Japan, although continued monitoring is warranted.
33 63

34 64 **Funding:** Grants-in-Aid for Cancer Control Policy from the Ministry of Health, Labour, and Welfare,
35 65 Japan (20EA1017); Japan Agency for Medical Research and Development (AMED: 22ck0106778h0001)
36 66

37 67 **Keywords:** COVID-19 pandemic; mortality trends; vital statistics; increase in mortality; Japan
38 68
39 69
40 70
41 71
42 72

1
2
3
4
5
6 **73 Strengths and limitations of this study**

- 7 74 • We comprehensively analysed mortality in Japan from the Ministry of Health, Labour, and Welfare
8 75 published the 2021 complete mortality data for the Japanese population.
9
10 76 • To analyse the contribution of the cause of death to annual all-cause age-standardized mortality rates
11 77 (ASMRs) changes, the cause-specific ASMR changes in comparison with those of the previous year
12 78 were calculated.
13
14 79 • This study is a descriptive analysis, and therefore, further analysis is needed to clarify the
15 80 quantitative impact such as ‘excess deaths’.
16
17 81 • In addition, long-term monitoring is necessary from 2022 onwards, especially for deaths from
18 82 chronic diseases that may have long-term effects by changes in lifestyle and medical care.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

109 Introduction

110 Approximately three years into the pandemic, the impact of COVID-19 on Japan continues to increase.
111 Although the Japanese government did not introduce strict COVID-19 restrictions such as lockdown,
112 people's daily lives were affected, as were the lives of health-care workers since the first declaration of a
113 state of emergency in April 2020. To date, however, no nationwide mortality data that discuss the impact
114 of the COVID-19 pandemic on mortality trends have been reported in Japan. Careful assessment of the
115 impact of the pandemic on population health would aid in the evaluation of efforts during the pandemic
116 and identify lessons, not only for Japan but also globally.

117 In most high-income countries, life expectancy in 2020 was shorter than that before, attributable to
118 both the direct and indirect effects of COVID-19.[1] For example, reductions in life expectancy in 2020
119 were observed in Russia, the U.S., Spain, England/Wales, Netherlands, Sweden, and France.[2] However,
120 in Japan, life expectancy was not shortened in 2020 according to the Japanese Ministry of Health, Labour
121 and Welfare (MHLW),[1,3] a deviation from the decreasing trend in most countries.[1]

122 Reasons for the prolonged life expectancy in 2020 despite the pandemic are unclear. One reason
123 could be that Japan did not experience as large a number of COVID-19 cases that year as other countries.
124 However, Japan experienced a six-fold increase in the number of reported cases from 2020 to 2021: 234
125 109 cases in 2020 and 1 492 874 cases in 2021.[4] Thus, annual mortality rate in 2021 in Japan may differ
126 from the stable downward trend seen before 2020. This study aimed to explore the long-term mortality
127 trends and cause-specific contributions during the COVID-19 pandemic in Japan, focusing on the years
128 2020 and 2021.

130 Methods

131 We illustrated changes in life expectancy between 2019 and 2020 for selected countries, including Japan,
132 using data extracted from the World Development Indicators managed by the World Bank.[1] To evaluate
133 the trends in the number of COVID-19 cases in Japan, we extracted data on the daily number of reported
134 COVID-19 cases from 16 January 2020 (the first case confirmed) to 1 January 2023 from Japanese
135 government records.[4] The numbers of deaths (5-year age intervals) between 1995 and 2021 were
136 extracted from the vital statistics (complete deaths record) in Japan managed by MHLW.[3] The 2021
137 complete mortality data were published in September 2022.[3] The vital statistics cover all Japanese
138 deaths that occurred in Japan. The relevant population data were also collected from the vital statistics
139 and population census.

140 We calculated age-standardized mortality rates (ASMRs) for all causes of death combined and
141 cause-specific deaths for major causes from 1995 to 2021 to assess trends in mortality rates. ASMRs were
142 calculated using the 2015 Japan Standard Population.[5] We further calculated the annual percent changes
143 in ASMRs before and during the early part of the COVID-19 pandemic (2020 and 2021). Causes of death
144 (the International Classification of Diseases 10th revision: ICD-10) included: certain infectious and

1
2
3
4
5
6 145 parasitic diseases (A00-B99), malignant neoplasms (C00-C97), heart diseases (I01-I02.0, I05-I09, I20-
7 146 I25, I27, I30-I52), cerebrovascular diseases (I60-I69), pneumonia (J12-J18), liver disease (K70-K76),
8 147 senility (R54), accidents (V01-X59), suicide (X60-X84), and COVID-19 (U07). These classifications
9 148 were based on the leading causes of death reported by the official mortality statistics from MHLW.[3]
10 149 MHLW follows the algorithm for classifying the causes of death based on ICD-10.

11
12
13 150 To analyse the contribution of the cause of death to annual all-cause ASMR changes, the cause-
14 151 specific ASMR changes in comparison with those of the previous year were calculated for six periods
15 152 from 2015–2016 to 2020–2021.

16
17 153

18 154 **Patient and public involvement**

19 155 Actual patients were not involved in this study of data.

20
21 156

22 157 **Results**

23
24 158 Figure 1 shows Japan was one of the countries where life expectancy was prolonged in 2020 despite
25 159 having shortened in many high-income countries such as the U.S. and France. Figure 2 shows trends in
26 160 the daily number of reported COVID-19 cases in Japan since 16 January 2020. The peak of reported
27 161 COVID-19 cases was observed in August 2022 (7th COVID-19 wave). While the absolute number of
28 162 COVID-19 cases was very small in 2020, the annual number of reported COVID-19 cases increased
29 163 rapidly in 2021 and 2022.

30
31 164 Figure 3 shows the trends in all-cause ASMRs (per 100 000 persons) between 1995 and 2021.
32 165 Supplement Table 1 shows the trends in number of deaths in Japan between 1995 and 2021. After the
33 166 Great East Japan Earthquake occurred in 2011, ASMRs continued decreasing until 2020, then increased
34 167 in 2021 in both sexes. For men, all-cause ASMRs (per 100 000 persons) were 1352.3 in 2019 (-1.69%
35 168 from 2018), 1328.8 in 2020 (-1.74% from 2019), and 1356.3 in 2021 (+2.07% from 2020). For women,
36 169 all-cause ASMRs were 746.0 in 2019 (-1.39% from 2018), 722.1 in 2020 (-3.20% from 2019), and 737.9
37 170 in 2021 (+2.19% from 2020). Age-specific analyses also showed stable to slightly increased mortality
38 171 trends during the period of COVID-19 pandemic (Supplement Figure 1). Supplement Figure 2 shows the
39 172 trends in cause-specific ASMRs between 1995 and 2021. For men, COVID-19 ASMRs were 3.8 in 2020
40 173 and 17.5 in 2021. For women, COVID-19 ASMRs were 1.5 in 2020 and 7.7 in 2021. ASMRs from
41 174 malignant neoplasms, pneumonia, accidents, and suicide (men only) decreased during the COVID-19
42 175 pandemic in Japan while the trend of cardiovascular disease (heart disease and cerebrovascular disease
43 176 combined) increased in 2021. In addition, the trend of suicide in women increased in 2020. Supplement
44 177 Figure 3 shows trends in malignant neoplasms ASMRs by cancer site. Trends in most malignant
45 178 neoplasms were decreased or stable, which was not altered compared to the trends before 2020.

46
47 179 Figure 4 shows the cause-specific contribution to annual changes in all-cause ASMR. The analysis
48 180 of annual ASMR changes revealed that decreases in malignant neoplasms, pneumonia, heart disease, and

1
2
3
4
5
6 181 cerebrovascular diseases continuously contributed to substantial annual mortality reductions for both
7 182 sexes during 2015–2019; however, the contributions to reduction disappeared for cardiovascular disease
8 183 from 2020 to 2021. COVID-19 (+13.7 per 100 000 for men and +6.2 per 100 000 for women in
9 184 comparisons with the previous year) and senility (+7.4 per 100 000 for men and +8.1 per 100,000 for
10 185 women in comparisons with the previous year) largely contributed to the mortality increases from 2020 to
11 186 2021. Also, ‘other causes not classified major causes’ contributed to all-cause mortality increase as well
12 187 from 2020 to 2021.
13 188

14 189

15 190 **Discussion**

16 191 This is the first study to comprehensively report on mortality analysis in Japan since MHLW published
17 192 the 2021 complete mortality data for the Japanese population. We found that the numbers of deaths from
18 193 COVID-19 were 9 732 (1.32% of all deaths) for men and 7 034 (1.00% of all deaths) for women in 2021,
19 194 a substantial increase from the year 2020 (2 094 deaths for men and 1 372 deaths for women). The
20 195 number of deaths in the population due to diagnosed COVID-19 was relatively low compared to many
21 196 other high-income countries.[6] In both men and women, all-cause ASMR decreased gradually every year
22 197 from 2011 to 2020 and increased from 2020 to 2021, with a slightly greater decrease in women than in
23 198 men between 2019 and 2020. In Japan, declining trends in all-cause mortality reversed in 2021 for the
24 199 first time since the Great East Japan Earthquake occurred in 2011.

25 200 The mortality trend varied by cause of death. The patterns of mortality change during the COVID-19
26 201 pandemic could be classified into the following three categories: (1) stable mortality decline (e.g. certain
27 202 infectious and parasitic diseases, malignant neoplasms, and pneumonia), (2) stable mortality increase (e.g.
28 203 senility), and (3) reversal of decreasing mortality trend (heart diseases, cerebrovascular diseases, suicide
29 204 for women). Considering these changes, a substantial mortality increase from COVID-19 and senility
30 205 resulted in an all-cause mortality increase in 2021 while malignant neoplasms and pneumonia contributed
31 206 to mortality declines.

32 207 Recorded mortality from malignant neoplasms declined during the COVID-19 pandemic, despite
33 208 that patients diagnosed with a cancer regardless of COVID-19 status were required to postpone non-
34 209 urgent surgeries, suspend outpatient visits, and change treatment methods. Indeed, the numbers of cancer
35 210 diagnoses, the cancer screening, outpatient visits, and surgical procedures in 2020 have been reported to
36 211 be lower than those before 2019.[7-10] Those reports have raised deep concern about potential
37 212 consequences, such as delays in diagnosis and care, decreased patient survival, and increased population
38 213 mortality; however, our findings revealed a decrease in 2020 and no obvious change in cancer mortality,
39 214 at least in 2021. Nevertheless, further monitoring is necessary because the delays in diagnosis and
40 215 treatment can exert a belated effect on mortality.

41 216 We found that the ASMR from cardiovascular disease increased in 2021. The loss of reduction
42 217 trends of cardiovascular disease partially resulted in increasing all-cause mortality in 2021 for both sexes.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 217 This is supported by another study reporting excess deaths from cardiovascular disease from April to May
7 218 2021.[11] As a direct pathway, the COVID-19 pandemic may have caused an increase in the prevalence
8
9 219 of severe heart disease for the Japanese population because COVID-19 is suggested to be a risk factor for
10 220 acute myocardial infarction and ischemic stroke.[12] In addition, the pandemic might have induced a
11 221 delay in emergency transport and delay in arrival at hospital, resulting in the loss of timely treatment. This
12
13 222 may be an indirect pathway through which mortality reductions of cardiovascular disease stagnated in
14
15 223 Japan.

16 224 A substantial increase in mortality due to senility has been occurring since the mid-2000s,
17
18 225 independent of the pandemic. This can be interpreted as a result of the rapid aging of the Japanese
19 226 population. Although we applied age-standardization for mortality analysis, the increase in the absolute
20 227 number of deaths from senility, especially for the oldest old (85 years and over), resulted in an increase in
21 228 ASMR. During the pandemic, however, changes in patterns or places of medical care may have resulted
22
23 229 in more physicians reporting senility as the cause of death, especially deaths at home. Indeed, excess
24 230 deaths from senility at home have been observed since May 2020.[11] As such, for the elderly, both direct
25 231 and indirect death by COVID-19 may be miscoded to senility, which contributed to excess deaths in
26 232 2021. The sharp increase in deaths by ‘other causes not classified as major causes’ in 2021 (Figure 3) may
27
28 233 have occurred by a similar mechanism. Therefore, our findings suggest that senility and ‘other causes not
29 234 classified as major causes’ may largely represent the excess deaths in Japan during the pandemic. This
30
31 235 may also include underdiagnosis and potential misclassification of causes of death.

32
33 236 We found clear declines in mortality from infectious diseases (excluding COVID-19) and infectious
34 237 pneumonia since the pandemic began in Japan. This is likely because the countermeasures for COVID-19
35 238 such as wearing a mask, hand hygiene, and social distancing prevented these diseases. In addition, clear
36 239 mortality declines due to accidents were observed probably because fatal traffic accidents decreased due
37 240 to stay-at-home measures. These are positive outcomes of the COVID-19 measures; however, we
38 241 identified an increase in suicide rate among women in 2020 and 2021. The increase did not largely impact
39 242 on all-cause mortality changes for women but this is obviously a negative effect of the COVID-19
40 243 measures such as restrictions of economic activity (e.g. cancellation of events and shorter business hours
41 244 for restaurants).[13,14]

42
43 245 This study is a descriptive analysis of national mortality data and should accordingly be
44 246 interpreted with caution. Our findings suggest that the mortality increase in 2021 may be associated with
45 247 the increase in COVID-19 cases; however, further analysis is needed to clarify the quantitative impact
46 248 such as ‘excess deaths’. Also, long-term monitoring is necessary from 2022 onwards, especially for
47 249 deaths from chronic diseases that may have long-term effects by changes in lifestyle and medical care.

48 250 In conclusion, a sign of increasing mortality was observed in 2021 in the annual mortality rate in
49 251 Japan, although the impact of the COVID-19 pandemic on mortality in Japan still seems to be limited.
50 252 The observed increase in mortality was attributable to COVID-19, senility, cardiovascular disease, and
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 253 'other causes not classified as major cause'. Taking the rapidly increasing rate of COVID-19 cases in
7 254 2022 into consideration, further monitoring is warranted for the year 2022, which may reveal a larger
8 255 impact of the pandemic on mortality compared to that for 2020 and 2021.
9 256

10 257 **Ethics statements**

11 258 **Patient consent for publication**

12 259 Not applicable.

13 260 **Ethics approval**

14 261 Ethics approval was not applicable.

15 262 **Data availability**

16 263 This study used the vital statistics data from a portal site for Japanese Government Statistics (e-Stat:
17 264 <https://www.e-stat.go.jp/>), and data at an individual level were not used.
18 265

19 266 **Authors' contributions:** All author had full access to all the study data. H.T. was responsible for the
20 267 integrity of the data, the accuracy of the data analysis, and the drafting of the manuscript. All authors
21 268 contributed to the concept and design of the study. All authors critically reviewed the manuscript. K.K.
22 269 supervised the study and provided administrative, technical, and material support.

23 270 **Declaration of interest statement:** The authors have no conflicts of interest directly relevant to the
24 271 content of this study.

25 272 **Funding:** This research was supported by Grants-in-Aid for Cancer Control Policy from the Ministry of
26 273 Health, Labour, and Welfare, Japan (20EA1017) and Japan Agency for Medical Research and
27 274 Development (AMED; Grant Number: 22ck0106778h0001).

28 275 **Patient and other consents:** Not applicable.

29 276 **Availability of data and materials:** Data are available on request.

30 277 **Acknowledgment:** We thank Libby Cone, MD, MA, from Dmed
31 278 (www.dmed.co.jp <<http://www.dmed.co.jp/>>) for editing English drafts of this manuscript.
32 279

33 280 **Figure legends**

34 281 **Figure 1.** Changes in life expectancy between 2019 and 2020 for selected countries for both sexes

35 282 **Figure 2.** Trends in the daily number of reported COVID-19 cases in Japan since 16 January 2020


36 283 **Figure 3.** Trends in all-cause and cause-specific age-standardized mortality rates between 1995 and 2021

37 284 **Figure 4.** Cause-specific contribution to changes in all-cause age-standardized mortality rates (annual
38 285 comparisons with previous year): differences in changes in ASMR between 2020 and 2021 were
39 286 calculated as $(ASMR_{2021} - ASMR_{2020})$ for each cause-specific death, where ASMR=age standardized
40 287 mortality rate per 100 000 population.
41 288


289 **Reference**

- 290 1. The World Bank. Life expectancy at birth, total (years).
291 <https://data.worldbank.org/indicator/SP.DYN.LE00.IN> Date accessed: December 12, 2022
- 292 2. Islam N, Jdanov DA, Shkolnikov VM, et al. Effects of covid-19 pandemic on life expectancy
293 and premature mortality in 2020: time series analysis in 37 countries. *BMJ*. 2021;375:e066768.
- 294 3. Ministry of Health, Labour and Welfare. Vital Statistics.
295 <https://www.mhlw.go.jp/english/database/db-hw/vs01.html> Date accessed: December 12, 2022
- 296 4. Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19
297 infections. <https://covid19.mhlw.go.jp/en/> December 12, 2022
- 298 5. Tanaka H, Tanaka S, Togawa K, Katanoda K. Practical implications of the update to the 2015
299 Japan Standard Population: mortality archive from 1950 to 2020 in Japan. *J Epidemiol*. 2023;33:372-380
- 300 6. World Health Organization. WHO coronavirus (COVID-19) dashboard.
301 <https://covid19.who.int> December 12, 2022
- 302 7. Ikeda N, Yamamoto H, Taketomi A, et al. The impact of COVID-19 on surgical procedures in
303 Japan: analysis of data from the National Clinical Database. *Surg Today*. 2022;52:22-35.
- 304 8. Sato Y, Fujiwara Y, Fukuda N, et al. Changes in Treatment Behavior during the COVID-19
305 Pandemic among Patients at a Cancer Hospital. *Cancer Cell*. 2021;39:130-131.
- 306 9. Toyoda Y, Katanoda K, Ishii K, Yamamoto H, Tabuchi T. Negative impact of the COVID-19
307 state of emergency on breast cancer screening participation in Japan. *Breast Cancer*. 2021;28:1340-1345.
- 308 10. Okuyama A, Watabe M, Makoshi R, Takahashi H, Tsukada Y, Higashi T. Impact of the
309 COVID-19 pandemic on the diagnosis of cancer in Japan: analysis of hospital-based cancer registries. *Jpn*
310 *J Clin Oncol*. 2022;52:1215-1224.
- 311 11. Nomura S, Eguchi A, Ghaznavi C, et al. Excess deaths from non-COVID-19-related causes in
312 Japan and 47 prefectures from January 2020 through May 2021 by place of death. *SSM Popul Health*.
313 2022;19:101196.
- 314 12. Katsoularis I, Fonseca-Rodriguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of
315 acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case
316 series and matched cohort study. *Lancet*. 2021;398:599-607.
- 317 13. Sakamoto H, Ishikane M, Ghaznavi C, Ueda P. Assessment of Suicide in Japan During the
318 COVID-19 Pandemic vs Previous Years. *JAMA Netw Open*. 2021;4:e2037378.
- 319 14. Kikuchi K, Anzai T, Takahashi K. The Unusual Increase in Suicides Among Women in Japan
320 During The COVID-19 Pandemic: A Time-Series Analysis until October 2021. *J Epidemiol*. 2023; 33:
321 45-51.


Changes in life expectancy between 2019 and 2020, years




28
29
30
31
32
33
34
35
36




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41



(A) Men



(B) Women




Appendix Table 1. Number of deaths in Japan between 1995 and 2021*


Year	Men					Women				
	All-cause	Malignant neoplasms	Heart disease	Cerebrovascular disease	COVID-19	All-cause	Malignant neoplasms	Heart disease	Cerebrovascular disease	COVID-19
1995	501276	159623	69718	69587	-	420863	103399	69488	76965	-
1996	488605	164824	68977	66479	-	407606	106359	69252	73887	-
1997	497796	167076	69776	65790	-	415606	108337	70398	72907	-
1998	512128	172306	71134	65529	-	424356	111615	71986	72290	-
1999	534778	175817	73979	66452	-	447253	114739	77100	72537	-
2000	525903	179140	72156	63127	-	435750	116344	74585	69402	-
2001	528768	181393	72727	63146	-	441563	119265	75565	68710	-
2002	535305	184033	74986	62229	-	447074	120535	77532	68028	-
2003	551746	186912	77989	63274	-	463205	122631	81556	68793	-
2004	557097	193096	77465	61547	-	471505	127262	82160	67508	-
2005	584970	196603	83979	63657	-	498826	129338	89146	69190	-
2006	581370	198052	82811	61348	-	503080	131262	90213	66920	-
2007	592784	202743	83090	60992	-	515550	133725	92449	66049	-
2008	608711	206354	86139	61121	-	533696	136609	95789	65902	-
2009	609042	206352	85543	59293	-	532823	137753	95202	63057	-
2010	633700	211435	88803	60186	-	563312	142064	100557	63275	-
2011	656540	213190	91298	59616	-	596526	144115	103628	64251	-
2012	655526	215110	92976	58625	-	600833	145853	105860	62977	-
2013	658684	216975	91445	56718	-	609752	147897	105278	61629	-
2014	660334	218397	92278	54995	-	612670	149706	104647	59212	-
2015	666707	219508	92142	53576	-	623737	150838	103971	58397	-
2016	674946	219846	93453	52718	-	633212	153242	104617	56635	-
2017	690770	220416	96330	53198	-	649797	152949	108538	56698	-
2018	699138	218625	98035	52398	-	663332	154959	110186	55788	-
2019	707421	220339	98210	51768	-	673672	156086	109504	54784	-
2020	706834	220989	99304	50390	2094	665921	157396	106292	52588	1372
2021	738141	222467	103700	51594	9732	701715	159038	111010	53001	7034

*Malignant neoplasms (ICD-10: C00-C97); Heart diseases (I01-I02.0, I05-I09, I20-I25, I27, I30-I52); Cerebrovascular diseases (I60-I69); COVID-19 (U07)


(A) All cause (men, 0-44 years)




(B) All cause (women, 0-44 years)




(C) All cause (men, 45-69 years)




(D) All cause (women, 45-69 years)



(E) All cause (men, 70-95 years and over)




(F) All cause (women, 70-95 years and over)




Appendix Figure 1. Trends in crude mortality rate by five-year age groups between 1995 and 2021


(A) Certain infectious and parasitic diseases (A00-B99)




(B) Malignant neoplasms (C00-96)




(C) Heart diseases (I05-09, I20-25, I27, I30-51)




(D) Cerebrovascular diseases (I60-69)




(E) Pneumonia & Bronchitis (J12-18)




(F) Liver disease (K70-76)




(G) Senility (R54)




(H) Accidents (V01-X59)



(I) Suicide (X60-84)




(J) COVID-19 (U07)




Appendix Figure 2. Trends in cause-specific age-standardized mortality rates by cancer site between 1995 and 2021


(A) Oral cavity and pharynx (C00-14)




(B) Esophagus (C15)




(C) Stomach (C16)




(D) Colon (C18)




(E) Rectum (C19-20)




(F) Liver (C22)




(G) Gallbladder and bile ducts (C23-24)




(H) Pancreas (C25)




(I) Larynx (C32)




(J) Lung, trachea (C33-34)




(K) Skin (C43-44)




(L) Breast (C50)




(M) Uterus (C53-55)




(N) Ovary (C56)




(O) Prostate (C61)




(P) Bladder (C67)



(Q) Brain, nervous system (C70-72)




(R) Malignant lymphoma (C81-85, C96)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(S) Leukemia (C91-95)



Appendix Figure 3. Trends in cancer age-standardized mortality rates by cancer site between 1995 and 2021

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found		RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	Title (line 1-2), abstract (line 38-44)
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported			Introduction (line 109-121)
Objectives	3	State specific objectives, including any prespecified hypotheses			Introduction (line 122-128)
Methods					
Study Design	4	Present key elements of study design early in the paper			Method (line 131-139)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection			Method (line 131-139)

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27</p> <p>Participants</p>	<p>6</p>	<p>(a) <i>Cohort study</i> - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>		<p>RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	<p>Method (line 131-139)</p>
<p>28 29 30 31 32 33 34</p> <p>Variables</p>	<p>7</p>	<p>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.</p>		<p>RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.</p>	<p>Method (line 140-149)</p>
<p>35 36 37 38 39 40 41 42</p> <p>Data sources/ measurement</p>	<p>8</p>	<p>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</p>			<p>Method (line 131-139)</p>

1 2 3 4	Bias	9	Describe any efforts to address potential sources of bias		None.
5 6 7 8 9	Study size	10	Explain how the study size was arrived at		None.
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why		Method (line 140-149)
35 36 37 38 39 40 41 42 43 44 45 46 47	Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses		Method (line 140-149)
	Data access and cleaning methods		..	RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.	Data availability (line 261-263)

				RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	
Linkage		..		RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	None.
Results					
Participants	13	(a) Report the numbers of individuals at each stage of the study (<i>e.g.</i> , numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram		RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Results (line 158-163)
Descriptive data	14	(a) Give characteristics of study participants (<i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i> , average and total amount)			Results (line 158-163)
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report numbers in each exposure			Results (line 164-178)

		category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures			
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period			Results (line 164-187)
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses			None.
Discussion					
Key results	18	Summarise key results with reference to study objectives			Discussion (line 190-198)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias		RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Discussion (line 244-248)
Interpretation	20	Give a cautious overall interpretation of results considering objectives,			Discussion (line 199-243)

		limitations, multiplicity of analyses, results from similar studies, and other relevant evidence			
Generalisability	21	Discuss the generalisability (external validity) of the study results			None.
Other Information					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based			Funding (line 271-273)
Accessibility of protocol, raw data, and programming code		..		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	None.

*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.